Neeraj Verma*

Department of Pharmacology, Hygia College of Pharmacy, Lucknow, Uttar Pradesh, India

*Corresponding Author: Neeraj Verma, Department of Pharmacology, Hygia College of Pharmacy, Lucknow, Uttar Pradesh, India.

Received: January 10, 2024; Published: January 31, 2024

Abstract

Dementia is a progressive neurodegenerative disorder characterized by a decline in cognitive abilities, affecting memory, thinking, behaviour, and daily functioning. It poses a significant global health challenge due to its prevalence, impact on individuals, families, and healthcare systems, and the lack of a cure. It is a syndrome caused by various underlying diseases and conditions, including Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal dementia. It predominantly affects older adults, with the prevalence increasing with age. The primary risk factor for dementia is advanced age, although genetic factors, cardiovascular diseases, lifestyle factors, and traumatic brain injury also contribute. The clinical features of dementia include memory loss, impaired judgment, difficulties with language and communication, changes in mood and behaviour, and challenges with daily activities. Diagnosis is typically made through a combination of clinical assessment, cognitive testing, medical history evaluation, and neuroimaging. Early detection and accurate diagnosis are crucial to initiate appropriate management strategies. Management of dementia involves a multidimensional approach aimed at improving quality of life, maintaining independence, and addressing the specific needs of individuals and their caregivers. Non-pharmacological interventions, such as cognitive stimulation, physical exercise, and social engagement, play a significant role in symptom management and slowing disease progression. Pharmacological treatments may be prescribed to manage cognitive symptoms and behavioural disturbances.

Dementia is a complex and multifaceted condition with profound implications for individuals and society. Early diagnosis, supportive care, and tailored interventions are essential for optimizing outcomes and enhancing the well-being of individuals living with dementia and their caregivers. Further research and public health initiatives are necessary to develop effective preventive strategies and therapeutic interventions for this growing global health concern.

 Keywords: Dementia; Cognitive; Neurodegenerative Diseases; Alzheimer's Disease; Neuroimaging

References

1. Livingston G., et al. “Dementia prevention, intervention, and care: 2020 report of the Lancet Commission”. The Lancet10248 (2020): 413.
2. Xu W., et al. “Meta-analysis of modifiable risk factors for Alzheimer's disease”. Journal of Neurology, Neurosurgery, and Psychiatry 7 (2020): 745-754.
3. Van Deerlin VM., et al. “Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions”. Nature Genetics3 (2017): 234-239.
4. Ritchie CW., et al. “The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline data release V500.0”. The Journal of Prevention of Alzheimer's Disease3 (2018): 135-143.
5. Cummings J., et al. “Alzheimer's disease drug development pipeline: 2018”. Alzheimers and Dementia (N Y) 4 (2018): 195-214.
6. Prince M., et al. “The global prevalence of dementia: A systematic review and meta-analysis”. Alzheimers and Dementia 1 (2011): 63-75.
7. Langa KM., et al. “A comparison of the prevalence of dementia in the United States in 2000 and 2012”. JAMA Internal Medicine 1 (2017): 51-58.
8. Ryman DC., et al. “Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis”. Neurology 3 (2014): 253-260.
9. Liu CC., et al. “Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy”. Nature Reviews Neurology2 (2013): 106-118.
10. Gottesman RF., et al. “Impact of midlife hearing loss on the risk of dementia: The Atherosclerosis Risk in Communities Neurocognitive Study”. JAMA Neurology1 (2021): 1-10.
11. Satizabal CL., et al. “Circadian rest-activity rhythms and cognitive decline in older adults”. Neurology 10 (2020): e1005-e1016.
12. McKhann GM., et al. “The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease”. Alzheimer's and Dementia3 (2011): 263-269.
13. Błaszczyk JW. “Nigrostriatal interaction in the aging brain: New therapeutic target for Parkinson's disease”. Acta Neurobiologiae Experimentalis 77 (2017): 106-112.
14. Barbour JA and Turner N. “Mitochondrial Stress Signaling Promotes Cellular Adaptations”. International Journal of Cell Biology 2014 (2014): 156020.
15. Brazill JM., et al. “NMNAT: It's an NAD+ synthase... It's a chaperone... It's a neuroprotector”. Current Opinion in Genetics and Development 44 (2017): 156-162.
16. Herrup K. “The contributions of unscheduled neuronal cell cycle events to the death of neurons in Alzheimer's disease”. Frontiers in Bioscience E4 (2012): 2101-2109.
17. Wu MF., et al. “Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs”. Journal of Physiology 554 (2003): 202-215.
18. Moreno-Gonzalez I and Soto C. “Misfolded protein aggregates: Mechanisms, structures and potential for disease transmission”. Seminars in Cell and Developmental Biology 22 (2011): 482-487.
19. Hoey SE., et al. “AMPA Receptor Activation Promotes Non-Amyloidogenic Amyloid Precursor Protein Processing and Suppresses Neuronal Amyloid- Production”. PLoS ONE 8 (2013): e78155.
20. Wilkins HM and Swerdlow RH. “Amyloid precursor protein processing and bioenergetics”. Brain Research Bulletin 133 (2017): 71-79.
21. Derecki NC., et al. “Microglia as a critical player in both developmental and late-life CNS pathologies”. Acta Neuropathology 128 (2014): 333-345.
22. Shahnawaz M., et al. “Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy”. Nature 578 (2020): 273-277.
23. Paulson OB., et al. “Cerebral Blood Flow Response to Functional Activation”. Journal of Cerebral Blood Flow and Metabolism 30 (2010): 2-14.
24. Perea G., et al. “Tripartite synapses: Astrocytes process and control synaptic information”. Trends in Neuroscience 32 (2009): 421-431.
25. Delezie J and Handschin C. “Endocrine Crosstalk Between Skeletal Muscle and the Brain”. Frontiers in Neurology 9 (2018): 698.
26. Kirk B., et al. “Muscle, Bone, and Fat Crosstalk: The Biological Role of Myokines, Osteokines, and Adipokines”. Current Osteoporosis Reports 18 (2020): 388-400.
27. Ben Haim L., et al. “Elusive roles for reactive astrocytes in neurodegenerative diseases”. Frontiers in Cell Neuroscience 9 (2015): 278.
28. Liu P., et al. “Altered arginine metabolism in Alzheimer’s disease brains”. Neurobiology Aging 35 (2014): 1992-2003.
29. Rahimian R., et al. “Microglial Inflammatory-Metabolic Pathways and Their Potential Therapeutic Implication in Major Depressive Disorder”. Frontiers in Psychiatry 13 (2022): 871997.
30. Riske L., et al. “Lactate in the brain: An update on its relevance to brain energy, neurons, glia and panic disorder”. Therapeutic Advances in Psychopharmacology 7 (2016): 85-89.
31. Sipione S., et al. “Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications”. Frontiers in Neuroscience 14 (2020): 572965.
32. Buyanova IS., et al. “Cerebral White Matter Myelination and Relations to Age, Gender, and Cognition: A Selective Review”. Frontiers in Human Neuroscience 15 (2021): 662031.
33. Yeatman JD., et al. “Lifespan maturation and degeneration of human brain white matter”. Nature Communication 5 (2014): 4932.
34. Dubois B., et al. “Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria”. Alzheimer's Dement 12 (2016): 292-323.
35. Hurtado-Chong A., et al. “IGF-I promotes neuronal migration and positioning in the olfactory bulb and the exit of neuroblasts from the subventricular zone”. European Journal of Neuroscience 30 (2009): 742-755.
36. Boustani M., et al. “Screening for dementia in primary care: A summary of the evidence for the US Preventive Services Task Force”. Annals of Internal Medicine 138 (2003): 927-937.
37. Kumar R., et al. “Diagnostic role of imaging in dementia: An update”. Clinical Radiology 70 (2015): 815-827.
38. Jorm AF. “The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): A review”. International Psychogeriatry 16 (2004): 275-293.
39. Lei X., et al. “The traditional medicine and modern medicine from natural products”. Molecules 24 (2019): 1-17.
40. Chan WL., et al. “Efficacy of physical exercise in preventing cognitive decline in elderly individuals with dementia: A systematic review”. International Journal of Geriatric Psychiatry 35 (2020): 614-621.
41. Chien WT., et al. “Randomized controlled trial of a dementia care programme for families of home-resided older people with dementia”. Journal of Advanced Nursing 67 (2011): 774-787.
42. Brodaty H., et al. “Why caregivers of people with dementia and memory loss don't use services”. International Journal of Geriatric Psychiatry 28 (2013): 232-238.
43. Yamada T., et al. “Japanese and Asian regional characteristics of dementia-friendly communities designated by the Japanese government: An analysis of evaluation indicators collected nationwide”. Geriatrics and Gerontology International 20 (2020): 1059-1066.
44. Wong J., et al. “Telehealth-based dementia care during COVID-19 pandemic: Experience from a specialized clinic”. Clinical Interventions in Aging 16 (2021): 1-8.
45. Chien WT., et al. “Reducing subjective caregiver burden and enhancing quality of life for informal caregivers of people with dementia: A systematic review of psychosocial interventions”. Aging Mental Health 20 (2016): 791-803.
46. Boustani M., et al. “Screening for dementia in primary care: A summary of the evidence for the US Preventive Services Task Force”. Annals of Internal Medicine11 (2003): 927-937.
47. Chien WT., et al. “Reducing subjective caregiver burden and enhancing quality of life for informal caregivers of people with dementia: A systematic review of psychosocial interventions”. Aging and Mental Health8 (2016): 791-803.
48. Wong J., et al. “Telehealth-based dementia care during COVID-19 pandemic: Experience from a specialized clinic”. Clinical Interventions in Aging 16 (2021): 1-8.
49. Yamada T., et al. “Japanese and Asian regional characteristics of dementia-friendly communities designated by the Japanese government: An analysis of evaluation indicators collected nationwide”. Geriatrics and Gerontology International11 (2020): 1059-1066.

Citation

Citation: Neeraj Verma. “Revolutionizing Dementia Management: Insights and Progress from the Asian Pacific Region”.Acta Scientific Medical Sciences 8.2 (2024): 63-72.

Copyright

Copyright: © 2024 Neeraj Verma. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.